Product logins

Find logins to all Clarivate products below.


chevron_left

Stirred & Shaken: Navigating Potential Disruptions at the U.S. National Institutes of Health

Speakers

The U.S. National Institutes of Health has long underpinned America’s biomedical leadership. But the Trump administration’s sudden 15% cap on indirect cost reimbursements, down from 40–75%, has sent shockwaves through academic research, biopharma, and medtech.

In this on-demand webinar, Clarivate experts unpack the $4 billion cut’s far-reaching impacts—from therapeutic pipeline erosion and medtech market volatility to challenges for HBCUs and safety risks in NIH-affiliated clinical trials.

Watch to explore:

  • SBIR/STTR delays and early-stage discovery risks
  • Sequencing market shakeouts and reagent pricing shifts
  • Legal challenges from 22 states
  • The future of VC in neglected diseases
  • How academic medical centers and smaller institutions are adapting